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Abstract
6,6,8-Triethyldesmosdumotin B (2) was discovered as a MDR–selective flavonoid with significant
in vitro anticancer activity against a multi-drug resistant (MDR) cell line (KB-VIN) but without
activity against the parent cells (KB). Additional 2-analogues were synthesized and evaluated to
determine the effect of B-ring modifications on MDR-selectivity. Analogues with a B-ring Me (3)
or Et (4) group had substantially increased MDR–selectivity. Three new disubstituted analogues,
35, 37 and 49, also had high collateral sensitivity (CS) indices of 273, 250 and 100, respectively.
Furthermore, 2–4 also displayed MDR-selectivity in an MDR hepatoma-cell system. While 2–4
showed either no or very weak inhibition of cellular P-glycoprotein (P-gp) activity, they either
activated or inhibited the actions of the first generation P-gp inhibitors verapamil or cyclosporin,
respectively.
Introduction
Incidences of drug resistance still present major and serious obstacles to the effective
chemotherapeutic treatment of cancer, despite many efforts to overcome it.1,2 Resistance to
one drug often implies simultaneous resistance to structurally and mechanistically diverse
anticancer drugs. This efflux phenotype, called multidrug resistance (MDR),3,4 is in part
mediated by the over-expression of plasma membrane transporters, such as P-glycoprotein
(P-gp, MDR1 or ABCB1, localized at 7q21.1, a 170 kDa protein),5 MDR-associated
proteins (MRP1 or ABCC1, localized at 16p13.1, a 190 kDa protein, and MRP2),6 or breast
cancer resistant protein (BCRP or ABCG2, localized at 4q22, a 72 kDa protein).7–9 These
three kinds of proteins belong to the superfamily of ATP-binding-cassette (ABC)
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transporters.10 The emergence of MDR pumps causes cancer drugs to be pumped out of the
cell, thus reducing intracellular drug concentrations below cytotoxic levels. Because P-gp
has broad substrate specificity, tumor cells that over-express P-gp show resistance to many
classical and newer molecular-targeted antitumor drugs. The development of agents targeted
toward MDR1 or MRP1 is greatly needed in order to improve anticancer chemotherapeutic
strategies. MDR1/P-gp is a well-characterized efflux system and a major mediator of MDR.
11–14 Intrinsic or acquired over-expression of P-gp dramatically reduces drug response, at
times to less than one-quarter, causing poor clinical outcomes following chemotherapy.15
To date, the major pharmacological approaches to overcome MDR have focused on
inhibition of the pump function and/or down-regulation of pump over-expression.16–19
Numerous pump inhibitors (or modulators) have been found, and are generally classified as
first, second, or third generation chemosensitizers. Many second and third generation
inhibitors, such as valspodar, zosuquidar, and tariquidar, are more potent and less toxic than
first generation compounds like verapamil (VERAP) or cyclosporine A (CSA). Although
some of these new generation compounds are still in clinical trials, the benefits of
chemosensitization remain disappointing, in part because the modulator causes undesirable
changes in drug pharmacokinetics.20
Flavonoids are the most widespread natural compounds produced in plants, and they exhibit
diverse, important biological activities, including antioxidant, anticarcinogenic,
antiinflammatory, antiproliferative, antiangiogenic and antiestrogenic effects.21 Many
reports have demonstrated that flavonoids can also interact with ABC transporters and some
act as P-gp modulators.22–25 We found that the flavonoid desmosdumotin B (1, Figure 1)
exerted unique in vitro anticancer activity against a P-gp expressing MDR tumor cell line
(KB-VIN, ED50 = 2.0 µg/mL), resulting in a >20 fold index of selectivity over the drug
sensitive KB parent cell line.26 We also discovered that 6,8,8-triethyldesmosdumotin B
(TEDB, 2) and its 4′-methyl (3) and 4′-ethyl (4) analogues were significantly more potent
and showed MDR-selectivity of >250.27 In contrast, the related 6,8,8-tripropyl as well as
6,8-diethyl compounds were less optimized for MDR-selectivity.
The hypersensitivity of drug-resistance was first reported using Escherichia coli in 1952,
and the phenomenon was termed “collateral sensitivity” (CS).28 A significant CS agent
should show at least two-fold greater activity against the MDR line than the parental line.
Recently, Hall et al published a review concerning CS, and argued that exploiting CS
agents, which especially kill MDR cancer cells, is an exciting challenge and opportunity for
new drug discovery as well as clinical development.29 A thiosemicarbazone derivative
(NSC73306) was discovered through the US National Cancer Institute (NCI) anticancer
drug screen as a drug lead for targeting MDR tumor cell populations, and several derivatives
showed improved MDR-selectivity.30,31 While it was toxic toward a diverse panel of Pgp-
expressing tumor cell lines, the CS index was only 7.3-fold at best. Thus, the MDR-
selectivity of 2 and its known active analogues is substantially better, but many questions
remain about these unique flavonoids. In this report, we address some critical issues by
looking at effects on P-gp function, in vitro anticancer activity using a second drug-selected
(hepatoma) MDR-cell system, and general mode and mechanism of cytotoxicity. We also
explored structure-activity relationship (SAR) results for this unique compound class with
major focus on the modification of B-ring substituents.
Chemistry
Generally, analogues 5–55 were synthesized through a three-step sequence, Claisen-Schmidt
condensation of 5626 with a substituted benzaldehyde (ArCHO), cyclization to form the
pyranone A-ring, and C-7 demethylation with BBr3 as shown in Scheme 1. Because the C-7
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methoxy group was removed faster than a phenyl B-ring methoxy group, treatment with
BBr3 was carried out at a low temperature to retain the latter group. Analogues 10 and 44–
46, which contain hydroxy groups, were obtained from the related methoxy (for 10, 44, and
45) or benzyloxy (for 46) phenylaldehydes. The methyl and benzyl ethers were cleaved at
the final stage to provide the alcohols. 4′-Bromomethylphenyl analogue 18 was produced by
BBr3 treatment when 4′-(methoxymethyl)benzaldehyde, derived from commercially
available [4-(dimethoxymethyl)phenyl]methanol, was used as the ArCHO. Analogues 2–4
were synthesized previously.
Results and Discussion
All synthesized 2-analogues were evaluated in vitro against two human tumor cell lines, the
KB-VIN cell line, an MDR P-gp expressing cloned subline stepwise selected using
vincristine, and its parental non-MDR KB cell line. The cytotoxic activity data including
KB/KB-VIN sensitivity are listed in Tables 1 (mono-substituted phenyl B-ring) and 2
(multi-substituted phenyl B-ring). Except for 10, 26, and 53, which showed no MDR
selectivity, all 2-analogues demonstrated greater cytotoxicity against KB-VIN than KB,
resulting in CS indices of over 2.0. Regarding the mono-substituted B-ring analogues (Table
1), 4′-Me (3) and 4′-Et (4) compounds inhibited KB-VIN cell growth most strongly with
ED50 values of 0.08 and 0.07 uM, and CS indices of 460 and 320, respectively. Other
compounds with significant KB-VIN inhibition (ED50 <2.0 uM) had the following rank
order: 11 (4′-OMe, ED50 = 0.68 uM), 6 (4′-iPr, ED50 = 1.08 uM), 22 (3′-OMe, ED50 = 1.22
uM), 15 (4′-SMe, ED50 = 1.38 uM), and 17 (4′-F, ED50 = 1.85 uM). Among of 4’-substitued
analogues, 2–19, compounds with a longer side chain (over three carbons), OH, CHO, and
CH2Br at the 4′-position or 2′-CF3 lost potency against KB-VIN and the order of
substituents by decreasing selectivity was as follows: Me, Et > H ≫ SMe, OMe > F > OEt >
OPr > CF3, etc.
Compounds 20–28 carry a single substitution on the C2′- or C3′-position of the benzene
ring. All of them, except 26, exhibited some degree of selectivity; however, they showed
lower activity against KB-VIN compared to the parent unsubstituted compound.
Regarding multi-substituted B-ring analogues (Table 2), except for 54, all analogues showed
potent cytotoxicity against KB-VIN. Among them, 35, 37, and 49 had notable CS indices of
273, 250, and 100, respectively. Multiple substitutions on the benzene ring of compounds
29–55 demonstrated that, in general, increased selectivity and activity towards KB-VIN is
afforded by small hydrophobic groups in C4’- and C3’-positions. The decreasing rank order
for selectivity was as follows: 3-Me-4-OMe (35); 3’-F-4’-OMe (37) > 3’,5’-diMe (49) > 3’,
4’-diMe (30) > 3’-Me-4’-F (55) > 2’,3’-diMe-4’-OMe (39), > 3’-Cl-4’-Me (31) = 3’-Cl-4’-
OMe (38) > 2’-F-5’-Me (54) > 3’,5’-diOMe (52) > 3’-F-4’-Me (32) > 2’,3’-diOMe (50), etc.
These results indicate that substitutions on C3′ and C4′ significantly contribute to the KB/
KB-VIN sensitivity. Especially, C3′-substitution was the most important for the activity
towards KB-VIN (see, for instance, the change in activity for the pairs of compounds 29 and
30, 34 and 35, 39 and 40, 48 and 49). It is unclear to what extent the methoxy and halogen
groups acting as hydrogen bond acceptors contribute to the observed changes.
The previously synthesized 2–4 were also evaluated in vitro against a human hepatoma
MDR cell system, and the data are shown in Table 3. Hep3B-VIN cells are P-gp-expressing
and selected using vincristine from the parent non-MDR Hep3B cell line. The CS indices
measured for 2–4 were 30, 21, and 8.5, respectively, which are lower than values against
KB-VIN cells. Interestingly, the order of potency was changed to 3 (GI50 0.35 µM) > 4
(GI50 0.72 µM) > 2 (GI50 1.57 µM), compared with that against KB-VIN [4 (ED50 0.068
µM) = 3 (ED50 0.085 µM) > 2 (ED50 1.07 µM)] (Tables 1 and 3). However, it is significant
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that all three compounds displayed selective in vitro anticancer action against the hepatoma-
derived MDR cell line, because this finding shows that the activity is not peculiar to a single
MDR-cell line.
The effects of 2–4 on P-gp function in KB VIN (MDR) cells was also investigated as shown
in Figure 2. Drug pumping activity and inhibition of P-gp were measured using the standard
calcein-AM loading assay as described under methods. Figure 2A shows the effects of
treatment 2, 3 or 4 compared with those of first generation competitive inhibitors VERAP
and CSA. The data show that the latter two prototype P-gp inhibitors stimulated calcein-AM
influx, while compounds 3 and 4 inhibited the pump but only very weakly over the
concentration range tested (as compared to the action of VERAP and CSA shown in Figure
2A), and compound 2 was inactive. These results indicated that 2 had no detectable effect on
P-gp function in KB-VIN cells, while 3 and 4 were weak inhibitors, but only at
concentrations much higher than those that induced CS. The effects of co-treatment with 2,
3, or 4 and a fixed concentration of an active inhibitor (2.5 µg/ml VERAP or 4 µg/mL CSA)
are shown in Figures 2B–D respectively. Interestingly, inhibition of P-gp activity was
influenced by co-treatment with each MDR-selective compound and the magnitude and type
of interaction depended on the identity of compound and P-glycoprotein inhibitor,
respectively. All three compounds stimulated calcein-AM influx upon co-treatment with
VERAP, but had the opposite effect when co-treated with CSA. The activation of VERAP
inhibition of Pg-p was clearly concentration-dependent over the range tested, while the
responses were dose-limiting and more complicated for CSA with compound 3 or 4.
Compound 2 possessed the weakest activity, and compounds 3 and 4 were substantially
more potent (compare accumulation of intracellular fluorescence between Figures 2B–D). A
direct correlation between P-gp functional effects (Figures 2B–D) and in vitro anticancer
activity against KB-VIN cells (Table 1) was not observed, although the rank-order of the
three compounds’ activity in both assays is apparent. In conclusion, compounds 2, 3 and 4
are not potent P-gp inhibitors (Figure 2A), although they can clearly influence interaction of
the enzyme with substrates/inhibitors in MDR cells.
As shown in Figure 3, compound 2 was evaluated against KB-VIN cells together with non-
toxic concentrations of P-gp modulators VERAP or the allosteric inhibitor flupenthixol. Co-
treatment of 2 with VERAP or flupenthixol (Z-isomer) partially reversed the in vitro
anticancer activity of 2, showing that the MDR-selectivity was dependent in-part on P-gp
function and consistent with the effect on P-gp activity measured using the co-incubation
treatment protocol. Similar results showing partial reversal of 3 and 4 MDR-selectivity were
observed (data not shown). Further analysis using suitable probe analogues will be needed to
determine if the agents interact directly with P-gp and to map possible interaction domains.
Cell death induced by 2 and effect of co-treatment with VERAP are shown in Figure 4. The
effect of 2 on apoptosis in KB-VIN cells was measured using a Cell Death Detection
ELISAPLUS kit (Roche Diagnostics, Mannheim, Germany). As shown in Figure 4A, one-day
treatment induced a dose-dependent increase in adsorbance associated with histone-
associated-DNA-fragments in the cytoplasm. The half-maximal effect occurred between 1–2
ug/ml of 2, consistent with in vitro anticancer activity (Table 1). Co-treatment with VERAP
reversed the 2-induced DNA fragmentation. At one day post-treatment, immuno-blot
analysis clearly showed pro-caspase-3 cleavage, which again was prevented by VERAP co-
treatment (Fig 4B). These data demonstrate that 2 can induce classical apoptosis in KB-VIN
cells, and P-gp activity is implicated and required due to the antagonistic action of the pump
inhibitor.
Whether these effects are mediated via direct interaction with the P-gp enzyme (perhaps at
an allosteric site resulting in conformational change) or via indirect action (by affecting
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membrane properties and permeation of substrate/inhibitors) remain to be elucidated.
However, the current data are consistent with 2–4 being novel P-gp actives and suggest that
elucidation of the relationship between the MDR phenotype and the potent and selective in
vitro anticancer action is warranted and will be worthwhile.
Conclusions
In summary, all analogues demonstrated greater cytotoxicity against KB-VIN than KB,
resulting in CS indices of over 2.0, except for 10, 26, and 53. Among newly synthesized
analogues, 35, 37, and 49 displayed potent in vitro anticancer activity against KB-VIN, with
CS-ratios of 273, 250 and 100, respectively. These results indicated that substitutions on C3′
and C4′ significantly contribute to the KB/KB-VIN sensitivity.
Previously synthesized 2–4 also showed MDR selectivity against the drug-resistant human
hepatoma cell line Hep3B-VIN. While analogues 2–4 did not inhibit or only weakly
inhibited drug efflux P-gp pump activity, they either activated or inhibited the drug efflux
pump activity of prototype P-gp inhibitors VERAP and CSA, respectively. The flavonoid
compounds clearly influenced interaction of the enzyme with substrates/inhibitors in MDR
cells, although they did not inhibit P-gp. The MDR selectivity was reversed by co-treatment
with diverse P-gp inhibitors, such as VERAP or flupenthixol, suggesting dependence on
efflux pump activity, and 2-treatment induced apoptosis in KB-VIN cells.
Because of the unique bioactivity of this flavonoid series against P-gp over-expressing
tumor cell lines, we plan to explore detailed mechanism of action and preclinical application
studies on their potential as new cancer drugs.
Experimental Section
Chemistry. General
All chemicals and solvents were used as purchased. All melting points were measured on a
Fisher-Johns melting point apparatus without correction. 1H and 13C NMR spectra were
recorded on a Varian Gemini 2000 (300 MHz) NMR spectrometer with TMS as the internal
standard. All chemical shifts are reported in ppm. NMR spectra were referenced to the
residual solvent peak; chemical shifts δ in ppm; apparent scalar coupling constants J in Hz.
Mass spectroscopic data were obtained on a TRIO 1000 mass spectrometer. Analytical thin-
layer chromatography (TLC) was carried out on Merck precoated aluminum silica gel sheets
(Kieselgel 60 F-254). All target compounds were characterized by 1H-NMR, MS, and
elemental analyses. The purities of >95% were determined by 1H-NMR and elemental
analyses.
General synthetic procedures for 1-analogues
The aryl-substituted intermediate compound (57) was dissolved in 0.1% conc H2SO4 in
DMSO, then I2 (0.1 eq. mol) was added and the reaction mixture heated at 90–95 °C for 1 h.
The reaction mixture was quenched with ice-cold aq 10% Na2S2O3 and extracted with
EtOAc. The extract was washed with brine, dried over Na2SO4 and concentrated in vacuo.
The residue was chromatographed on silica gel eluting with EtOAc–hexane (1:4 to 1:2, v/v)
to afford the 7-methoxy substituted analogue (58), which was dissolved in anhydrous
CH2Cl2. The mixture was cooled to −78 °C. BBr3 (3 eq. mol, 1.0 M solution in CH2Cl2)
was added to the solution, which was warmed to 0 °C spontaneously and stirred until the
starting material was consumed. After addition of water, the reaction mixture was extracted
three times with CH2Cl2. The extracts were combined, washed with brine, dried over
Na2SO4 and concentrated in vacuo. The residue was chromatographed on silica gel eluting
with EtOAc–hexane (1:4) to obtain the target compound (5–55). The physical data of
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representative compounds, 5 for 4′-substituted analog, 20 for 3′-substituted analog, 27 for 2′-
substituted analog, 29 for 2′,4′-disubstituted analog, 35 for 3′,4′-disubstituted analog, and 49
for 3′,5′-disubstituted analog are described below. Data for other compounds are in the
supporting information.
4′-Propyl-6,8,8-triethyldesmosdumotin B (5)
Pale yellow prisms, mp 169–170 °C (EtOAc-Hexane). 1H NMR (300 MHz, CDCl3): δ 13.14
(s, 1H, 5-OH), 7.72 (d, 2H, J = 8.2 Hz, Ar-H), 7.36 (d, 2H, J = 8.2 Hz, Ar-H), 6.87 (s, 1H, 3-
H), 2.69 (t, 2H, J = 7.3 Hz, 4′-CH2CH2CH3), 2.45 (q, 2H, J = 7.3 Hz, 6-CH2CH3), 2.33-2.19
(m, 2H, 8-CH2CH3), 2.07–1.92 (m, 2H, 8-CH2CH3), 1.76-1.62 (m, 2H, 4′-CH2CH2CH3),
1.04 (t, 3H, J = 7.4 Hz, 6-CH2CH3), 0.97 (t, 3H, J = 7.3 Hz, 4′-CH2CH2CH3), 0.67 (t, 6H, J
= 7.3 Hz, 8-CH2CH3). MS (ESI+) m/z: 381 (M++1). Anal. (C24H28O4) C, H, O.
3′-Methyl-6,8,8-triethyldesmosdumotin B (20)
Pale yellow prisms, mp 109–110 °C (EtOAc-hexane). 1H NMR (300 MHz, CDCl3): δ 13.09
(s, 1H, 5-OH), 7.64-7.56 (m, 2H, Ar-H), 7.49-7.39 (m, 1H, Ar-H), 6.89 (s, 1H, 3-H), 2.48 (s,
3H, 3′-CH3), 2.46 (q, 2H, J = 7.4 Hz, 6-CH2CH3), 2.34-2.20 (m, 2H, 8-CH2CH3), 2.08-1.93
(m, 2H, 8-CH2CH3), 1.04 (t, 3H, J = 7.4 Hz, 6-CH2CH3), 0.67 (t, 6H, J = 7.4 Hz, 8-
CH2CH3). MS (ESI+) m/z: 353 (M++1). Anal. (C22H24O4) C, H, O.
2′-Methoxy-6,8,8-triethyldesmosdumotin B (27)
Pale yellow prisms, mp 139–140 °C (EtOAc-hexane). 1H NMR (300 MHz, CDCl3): δ 13.24
(s, 1H, 5-OH), 7.70 (dd, 1H, J = 8.0, 1.6 Hz, 6′-H), 7.55 (ddd, 1H, J = 8.5, 7.4, 1.6 Hz, 4′-
H), 7.23 (s, 1H, 3-H), 7.13 (dd, 1H, J = 8.0, 7.4 Hz, 5′-H), 7.08 (d, 1H, J = 8.5 Hz, 3′-H),
2.46 (q, 2H, J = 7.4 Hz, 6-CH2CH3), 2.30-2.16 (m, 2H, 8-CH2CH3), 2.04-1.90 (m, 2H, 8-
CH2CH3), 1.04 (t, 3H, J = 7.4 Hz, 6-CH2CH3), 0.67 (t, 6H, J = 7.4 Hz, 8-CH2CH3). MS
(ESI+) m/z: 369 (M++1). Anal. (C22H24O5) C, H, O.
2′,4′-Dimethyl-6,8,8-triethyldesmosdumotin B (29)
Pale yellow prisms, mp 129–130 °C (EtOAc-hexane). 1H NMR (300 MHz, CDCl3): δ 13.14
(s, 1H, 5-OH), 7.35 (d, 1H, J = 8.5 Hz, 6´-H), 7.21-7.14 (m, 2H, 3′ and 5′-H), 6.59 (s, 1H, 3-
H), 2.1–2.38 (m, 2H, 6-CH2CH3), 2.43 (s, 3H, 2′or 3′-CH3), 2.41 (s, 3H, 2′ or 3′-CH3),
2.28-2.12 (m, 2H, 8-CH2CH3), 1.98-1.82 (m, 2H, 8-CH2CH3), 1.04 (t, 3H, J = 7.4 Hz, 6-
CH2CH3), 0.65 (t, 6H, J = 7.4 Hz, 8-CH2CH3). MS (ESI+) m/z: 389 (M++Na). Anal.
(C23H26O4) C, H, O.
4′-Methoxy-3′-methyl-6,8,8-triethyldesmosdumotin B (35)
Pale yellow prisms, mp 169–170 °C (EtOAc-hexane). 1H NMR (300 MHz, CDCl3): δ 13.26
(s, 1H, 5-OH), 7.65 (dd, 1H, J = 8.2, 2.5 Hz, 6′-H), 7.55 (d, 1H, J = 2.5 Hz, 2′-H), 6.96 (d,
1H, J = 8.2 Hz, 5′-H), 6.79 (s, 1H, 3-H), 3.93 (s, 3H, 4′-OCH3), 2.45 (q, 2H, J = 7.3 Hz, 6-
CH2CH3), 2.30 (s, 3H, 3′-CH3), 2.33-2.18 (m, 2H, 6- or 8-CH2CH3), 2.06-1.92 (m, 2H, 6- or
8-CH2CH3), 1.04 (t, 3H, J = 7.3 Hz, 6-CH2CH3), 0.67 (t, 3H, J = 7.3 Hz, 8-CH2CH3). MS
(ESI+) m/z: 383 (M++1). Anal. (C23H26O5) C, H, O.
3′,5′-Dimethyl-6,8,8-triethyldesmosdumotin B (49)
Pale yellow prisms, mp 138–139 °C (EtOAc-hexane). 1H NMR (300 MHz, CDCl3): δ 13.13
(s, 1H, 5-OH), 7.38 (br s, 2H, Ar-H), 7.24 (br s, 1H, Ar-H), 6.87 (s, 1H, 3-H), 3.95 and 3.89
(s, 3H each, 2′ and 3′-OCH3), 2.45 (q, 2H, J = 7.3 Hz, 6-CH2CH3), 2.43 (s, 6H, 3′ and 5′-
CH3), 2.32-2.20 (m, 2H, 8-CH2CH3), 2.06-1.92 (m, 2H, 8-CH2CH3), 1.04 (t, 3H, J = 7.4 Hz,
6-CH2CH3), 0.67 (t, 6H, J = 7.3 Hz, 8-CH2CH3). MS (ESI+) m/z: 399 (M++Na). Anal.
(C23H26O4) C, H, O.
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All stock cultures were grown in T-25 flasks. Freshly trypsinized cell suspensions were
seeded in 96-well microtiter plates at densities of 1500–7500 cells per well with compounds
added from DMSO-diluted stock. After three days in culture, attached cells were fixed with
cold 50% trichloroacetic acid and then stained with 0.4% sulforhodamine B. The absorbency
at 562 nm was measured using a microplate reader after solubilizing the bound dye. The
mean ED50 is the concentration of agent that reduces cell growth by 50% under the
experimental conditions and is the average from at least three independent determinations
that were reproducible and statistically significant. For the VERAP reversal experiments,
cells were co-treated with VERAP (1 µg/mL). Control experiments showed this
concentration had no effect on the replication of KB-VIN cells. The following human tumor
cell lines were used in the assay: KB (nasopharyngeal carcinoma) and KB-VIN (vincristine-
resistant KB subline). All cell lines were obtained from Lineberger Cancer Center (UNC-
CH) or from ATCC (rockville, MD), except KB-VIN, which was a generous gift of
Professor Y.-C. Cheng, Yale University. Cells were cultured in RPMI-1640 medium
supplemented with 25mM HEPES, 0.25% sodium bicarbonate, 10% fetal bovine serum, and
100 µg/mL kanamycin.
Detection of P-gp activity (calcein-AM loading assay)
Calcein-AM is a probe substrate of P-gp and is converted into a fluorescent derivative via
cellular enzymes. MDR cells give low intrinsic fluorescent signals with this probe substrate,
unless P-gp is inhibited and then relative fluorescence will increase (see Figure 2-A for
effects of classical P-gp inhibitors). For the assay, 10,000 KB-VIN (MDR) cells per well
were seeded into 96-well plates with RPMI-1640 medium containing 5% FBS and incubated
in a humidified incubator for adhesion and growth. After 24 h incubation, the indicated
concentrations of test compounds were added into wells for 30 min at 37°C. Medium was
aspirated then replaced with fresh medium containing 1 µM calcein-AM and indicated
compounds. After continuing culture for 30 min at 37 °C in the dark, medium was removed
and the plates were washed gently and quickly with cold isotonic (PBS) buffer in the dark.
Cells were lysed using hypotonic Tris-HCl buffer, and fluorescence was detected using an
ELISA reader (Ex. 494 nm, Em. 517 nm.). Composite data obtained from two or more
independent experiments were analyzed using Prizm™ (Graphpad Software, San Diego,
CA).
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Effect on P-gp function in KB-VIN cells
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Chemoprotection of 2 by MDR-1 modulators in KB-VIN cells. Co-treatment with non-toxic
concentrations of VERAP or flupenthixol partially reversed in vitro anticancer activity of 2
against MDR-1 cell line (measured by use of the anionic protein dye sulforhodomine-B
(SRB). These results show that a competitive substrate-type inhibitor (VERAP) and an
allosteric-type pump inhibitor (Flupent) can negate MDR-selective cytotoxicity.
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The effect of 2 on apoptosis in KB-VIN cells was measured using a Cell Death Detection
ELISAPLUS kit (Roche Diagnostics, Mannheim, Germany).
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Syntheses of TEDB Analogues
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Table 3
Activity of 2–4 against Hep3B and Hep3B-VIN
GI50 (µM)
Hep3B Hep3B-VIN Hep3B/Hep3B-VIN
2 47.57 1.57 30
3 7.31 0.35 21
4 6.09 0.72 8.5
paclitaxel 0.0004 16.17 -
vincristine 0.0029 6.86 -
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